Results 101 to 110 of about 107,669 (285)

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Antibiotic‐mediated immune modulation in periodontitis

Periodontology 2000, EarlyView.
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez, R. M. Arce, Camila Pinheiro Furquim, Cristiane Gonçalves, Alpdogan Kantarci, Magda Feres, Nidia C. Castro dos Santos   +6 more
wiley   +1 more source

IFN-gamma is associated with risk of Schistosoma japonicum infection in China.

, 2003
Before the start of the schistosomiasis transmission season, 129 villagers resident on a Schistosoma japonicum-endemic island in Poyang Lake, Jiangxi Province, 64 of whom were stool-positive for S.
Bickle, QD, Chen, SZ, Cousens, SN, Hu, LS, Ji, MJ, Shen, L, Su, C, Taylor, MG, Weir, RE, Wu, GL, Wu, HW, Xie, ZW, Zhang, Y, Zhang, ZS   +13 more
core   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

A second-generation anti TB vaccine is long overdue

Annals of Clinical Microbiology and Antimicrobials, 2004
Summary Mycobacterium bovis BCG vaccine significantly reduces the risk of tuberculosis by 50% and continues to be used to prevent tuberculosis around the world. However, it has been shown to be ineffective in some geographical regions.
López-Vidal Yolanda, Castañón-Arreola Mauricio   +1 more
doaj   +1 more source

Veterinary Tuberculosis Vaccine Development [PDF]

Clinical Infectious Diseases, 2000
Tuberculosis caused by Mycobacterium bovis in domestic livestock and wildlife is a significant problem in many countries worldwide. Wildlife reservoirs of tuberculosis confound programs for tuberculosis eradication from domestic livestock. Successful vaccination against tuberculosis in domestic animals or wildlife could contribute to tuberculosis ...
openaire   +2 more sources

Health Misinformation in Ethiopia: Myths, Media Dynamics, Public Response, and Policy Implications: A Narrative Review

Public Health Challenges, Volume 5, Issue 1, March 2026.
Abstract Background Health misinformation in Ethiopia undermines public trust and weakens the effectiveness of health interventions. Cultural beliefs, religious influences, and the expansion of digital media contribute to myths that fuel vaccine hesitancy, stigma, and delayed health‐seeking behavior.
Trhas Tadesse Berhe, Dube Jara, Dereje Kifle   +2 more
wiley   +1 more source

India's Health Diplomacy: Advancing Pharmaceutical and MedTech Leadership in the Global South

World Medical &Health Policy, Volume 18, Issue 1, March 2026.
ABSTRACT Health diplomacy has become a pivotal aspect of India's engagement with the Global South, intertwining foreign policy, public health, and global collaboration to address disparities while pursuing strategic interests. India's pharmaceutical industry, which accounts for nearly 20% of the world's generics, has positioned the nation as the ...
Gaurav Chanderprakash Mittal, Vijay Kumar Chattu, Prakash Narayanan, Rahul Clare, Cherian Varghese   +4 more
wiley   +1 more source

Viejos y nuevos enfoques para el desarrollo de vacunas contra la tuberculosis.

VacciMonitor, 2000
Do we need renewed efforts to develop new vaccines to fight tuberculosis? Epidemiological data show that the decrease of the already low incidence of tuberculosis has stopped in developed countries.
H. Bercovier
doaj